- Bob Marley
- Aug 1, 2024
- 4 min read
A lesser-known cannabinoid known as CBG has surprised scientists after a first-ever human clinical trial found that it appears to improve memory, while also “significantly” reducing anxiety and stress.
The non-intoxicating cannabinoid might not be as well-known as THC and CBD, for example, but as it’s grown in popularity, researchers at Washington State University (WSU) and the University of California at Los Angeles (UCLA) set out to investigate its therapeutic potential amid anecdotal, survey-based reports about its therapeutic potential.
The study, published in the journal Scientific Reports this month, found that cannabigerol, or CBG, caused a “significant overall reductions in anxiety as well as reductions in stress” among study participants compared to the placebo. “CBG also enhanced verbal memory relative to placebo,” with “no evidence of subjective drug effects or impairment.”
That finding about CBG’s effects on memory took the research team by surprise. Lead author and WSU associate professor of psychology Carrie Cuttler said in a press release that they “triple-checked to ensure accuracy, and the enhancement was statistically significant.”
“Relative to placebo, there was a significant main effect of CBG on overall reductions in anxiety as well as reductions in stress… CBG also enhanced verbal memory relative to placebo.”
“The finding that it significantly enhanced [memory] was kind of shocking to me and completely, entirely unexpected, which was why I triple-checked the direction and the result,” Cuttler told Marijuana Moment in a phone interview on Wednesday, adding that “we definitely want to replicate that finding before we make too big of a deal about it.”
Cannabigerol #CBG had promising clinical trial results: reducing anxiety without the intoxication typically associated with whole plant #cannabis — #WSU-led studyhttps://t.co/mfOmmm2qoS
— WSU News (@WSUNews) July 31, 2024
To assess the efficacy of CBG, researchers conducted a double-blind, placebo-controlled field trial where 34 healthy adults were given either 20mg of hemp-derived CBG or a placebo tincture over two sessions.
Participants were first asked to complete online assessments rating their anxiety, stress and mood. After administering the cannabinoid, they took another series of assessments, including a survey, stress test and verbal memory test.
“CBG may represent a novel option to reduce stress and anxiety in healthy adults,” the study authors said. “Results indicate that CBG reduces global feelings of anxiety and stress and that it may enhance memory in the absence of intoxication, impairment, or subjective drug effects.”
“CBG reduces subjective ratings of anxiety and stress in healthy cannabis-using adults in the absence of motor or cognitive impairment, intoxication, or other subjective drug effect.”
On average, cannabigerol was linked to an average 26.5 percent reduction in feelings of anxiety, and researchers also found a “significant effect of CBG on subjective stress ratings.”
But the results of the verbal memory test, which involved having participants listen to and immediately recall two sets of 16 words, were especially surprising to the research team.
“We hypothesized that CBG would not impair memory, but our finding that CBG significantly verbal memory was unexpected,” the study says.
Asked by Marijuana Moment whether she had any thoughts about why CBG might uniquely enhance memory, Cuttler said her working theory was that the reduced anxiety people feel after consuming the cannabinoid could potentially be at play. That is, the cognitive function could be bolstered when people are feeling less stressed or anxious.
The clinical trial was informed by an earlier survey that found 51 percent of people who use CBG say they primarily consume it to mitigate anxiety. Nearly 80 percent of CBG users said it was more effective at treating anxiety than conventional anxiety medications.
“CBG is becoming increasingly popular, with more producers making bold, unsubstantiated claims about its effects,” Cuttler said. “Our study is one of the first to provide evidence supporting some of these claims, helping to inform both consumers and the scientific community.”
Cuttler cautioned that the researchers don’t want the results of this novel study to give people the impression that “CBG is a miracle drug.”
“It’s new and exciting, but replication and further research are crucial,” she said. “Ongoing and future studies will help build a comprehensive understanding of CBG’s benefits and safety, potentially offering a new avenue for reducing feelings of anxiety and stress without the intoxicating effects of THC.”
Cuttler said she’s currently awaiting approval to carry out a follow-up clinical trial that would be conducted in-person in a laboratory setting, rather than via Zoom as was the case in this latest study, so that the team can substantiate the findings and also assess the physiological effects of CBG such as its impacts on blood pressure, heart rate, cortisol levels and body temperature.
She’s also in initial talks about a separate study investigating how CBG might affect menopause symptoms, and she told Marijuana Moment she’s interested in hearing from potential participants who might want to be involved in that research.
Meanwhile, another recent first-of-its-kind study found that applying CBD-infused lotion to the skin appears to be tied to a lower risk of damage from exposure to ultraviolet (UV) rays.
A separate study on the possible therapeutic value of lesser-known compounds in cannabis that was published in the journal BioFactors says that a number of minor cannabinoids, including CBG, may have anticancer effects on blood cancer that warrant further study.
In May, industry-backed research into the potential anti-anxiety effects of cannabidiol separately found that an oral CBD solution effectively treated mild to moderate anxiety, as well as associated depression and poor sleep quality, with no serious adverse events observed.
CBD Lotion Tied To Reduced Skin Damage From UV Rays, New Study Finds
Photo courtesy of Mike Latimer.